A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis
Mariko Ogawa
Yoshiaki Furukawa- Laboratory for Mechanistic Chemistry of Biomolecules, Department of Chemistry, Keio University, Yokohama, Japan
Abnormal accumulation of protein inclusions in motor neurons has been known as a major pathological change in amyotrophic lateral sclerosis (ALS). Increasing numbers of proteins including mutant Cu, Zn-superoxide dismutase (SOD1) have been identified as constituents of pathological inclusions in a form of insoluble fibrillar aggregates. Notably, protein fibrillar aggregates exhibit a self-perpetuating property, which can convert a soluble native protein into insoluble fibrillar aggregates. Such “seeding reaction” of protein fibrils can accelerate the aggregation significantly and would contribute to the spread of inclusion pathologies from an affected cell to its neighboring cells in neurodegenerative diseases. In ALS, a pathological change first occurs at the site of disease onset and then propagates throughout the affected tissues in a time-dependent manner; therefore, it can be assumed that seeded aggregation may be the key factor of disease progression in ALS. In this mini review, we will briefly summarize recent studies on possible roles of a seeded aggregation of SOD1 in pathomechanism of ALS.
Introduction
Many proteins gain physiological functions by folding into their own unique three-dimensional structures, and any disturbance during this folding process potentially disrupts protein functions, which is considered to cause a variety of diseases (Morimoto, 2008). Among those, neurodegenerative diseases have been well characterized by abnormal accumulation of “mis”-folded proteins in brains and spinal cords of patients (Soto, 2003; Ross and Poirier, 2004). More specifically, certain misfolded proteins form insoluble, fibrillar aggregates that are rich in β-sheet structures, widely known as amyloid (Nelson et al., 2005).
In many neurodegenerative diseases, neurological symptoms appear in middle age (50 years ~), suggesting that it is a rare event for proteins to become misfolded/aggregated. In fact, protein fibrillar aggregation in vitro requires a significant conformational conversion of proteins to form oligomers (also known as “nucleus”), which is a rate-limiting step of the overall aggregation reaction (Harper and Lansbury, 1997). Once the nucleus forms, however, it functions as a structural template (or so called “seed”) to convert native proteins into β-sheet-rich structures and then elongate the protein fibril. This mechanism, which accelerates and even triggers protein aggregation, is called the seeding reaction. While it remains controversial whether protein aggregation is the direct cause or a mere result of neurodegeneration (Winklhofer et al., 2008; Treusch et al., 2009), this seeding mechanism may explain why many neurodegenerative diseases progress rapidly after the symptoms first appear.
One notable example for a seeding reaction is the infectivity of Prion diseases, in which the spread of fibrillar aggregates of prion proteins is considered to be the main cause of neurodegeneration (Prusiner, 1982; Aguzzi and Rajendran, 2009). Fibrils of prion proteins are considered to work as infectious agents that can be transmitted between individuals. As exemplified in kuru (Gibbs et al., 1980), eating affected tissues of the disease could introduce fibrillar prion aggregates into a brain of a healthy control as seeds and thereby trigger fibrillation of prion proteins and cause neurodegeneration. While no infectivity between individuals has been reported in neurodegenerative diseases besides prion diseases so far, a seeding phenomenon appears to be common to protein fibrillar aggregates (Dobson, 1999); therefore, increasing numbers of researchers have pursued possible roles of seeding reactions in pathologies of neurodegenerative diseases (Aguzzi and Rajendran, 2009; Polymenidou and Cleveland, 2011; Soto, 2012). For example, Alzheimer’s disease (AD) is characterized by fibrillar aggregation of Aβ peptides in brains (Hardy and Selkoe, 2002), and accelerated accumulation of Aβ fibrils has been confirmed in primate and rodent models that are injected with brain homogenates of an AD patient (Meyer-Luehmann et al., 2006; Ridley et al., 2006). Several other pathogenic proteins also forms fibrillar aggregates in vitro, which have been tested for their in vivo seeding activity by being transduced into cultured cells and brains of transgenic mouse model (Aguzzi and Rajendran, 2009; Polymenidou and Cleveland, 2011; Soto, 2012). A seeding reaction of protein fibrils is thus considered to play important roles in pathological progression of neurodegenerative diseases, and in this mini review, we will focus upon roles of seeded aggregation of proteins in pathologies of amyotrophic lateral sclerosis (ALS).
A Seeded Fibrillation of Superoxide Dismutase (SOD1) as a Pathological Propagation of Amyotrophic Lateral Sclerosis (ALS)
ALS is a devastating motor neuron disease, mainly caused by abnormal accumulation of inclusions in the spinal cord (Bruijn et al., 2004). Notably, ALS has been known to occur as a focal process, which spreads contiguously throughout upper and lower motor neurons (Ravits and La Spada, 2009; Holmes and Diamond, 2012; Kanouchi et al., 2012). In other words, motor neuron degeneration in ALS is an orderly and actively propagating process, which appears to share characteristics of a seeded aggregation of proteins seen in Prion diseases.
Most ALS cases (~90%) are sporadic with no known genetic factors (sporadic ALS, sALS), while the remaining cases have been known to exhibit a family history (familial ALS, fALS; Robberecht and Philips, 2013). In 1993, dominant mutations in the gene encoding Cu, Zn-superoxide dismutase (SOD1) were identified as one of major genetic causes of fALS (Rosen et al., 1993), and mutant SOD1 proteins have been known to accumulate abnormally in the form of insoluble inclusions within affected spinal motor neurons of SOD1-related fALS patients (Bruijn et al., 1998). Ultrastructural analysis of SOD1-positive inclusions in fALS cases has identified their fibrillar morphologies (Kato et al., 2000); however, those inclusions were not stained by amyloid-diagnostic dye, Thioflavin S, which has made it controversial whether fibrillar aggregates of mutant SOD1 in vivo are rich in β-sheets (Kerman et al., 2010). Moreover, SOD1-positive inclusions have never been isolated from fALS cases, so further biochemical tests will be required to characterize pathological SOD1 aggregates.
In contrast, SOD1-positive inclusions with ALS-like symptoms were reproduced in a fALS-model mouse expressing human SOD1 with a pathogenic mutation (Turner and Talbot, 2008) and were found to be stained by Thioflavin S, supporting the formation of amyloid-like, β-sheet-rich fibrils in mouse (Wang et al., 2002; Furukawa et al., 2008). Insoluble SOD1 aggregates were also successfully isolated from the spinal cords of affected fALS-model mice, and quite notably, those SOD1 aggregates exhibited seeding activity toward fibrillation of purified SOD1 proteins in vitro. Chia et al. have prepared homogenates of spinal cords of transgenic mice expressing human SOD1 with G93A mutation and shown that the homogenates triggered fibrillation of wild-type as well as G93A-mutant human SOD1 proteins under in vitro conditions with acidic pH of solution in the presence of a chaotropic reagent, guanidine hydrochloride (Chia et al., 2010). While destabilization of SOD1 proteins under artificial conditions appears to be required for a seeded acceleration of fibrillar aggregation, inclusions containing mutant SOD1 would function as seeds and thereby contribute to propagation of pathological changes among contiguous motor neurons and then disease progression of SOD1-related fALS cases.
Fibrillogenic propensities of SOD1 proteins have been well characterized in in vitro studies using purified recombinant proteins. SOD1 is a cytoplasmic enzyme (Chang et al., 1988) that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen (McCord and Fridovich, 1969) and is activated by binding of a catalytic copper and a structural zinc ion and also by forming an intramolecular disulfide bond (Furukawa et al., 2004). Wild-type holo-SOD1 with a disulfide bond exhibits high thermostability (Tm 90°C), conferring significant resistance to structural changes and aggregation (Forman and Fridovich, 1973). In contrast, when SOD1 lacks both metal ions and a disulfide bond (apo-SOD1SH), its melting temperature decreases down to 43°C and become more prone to misfolding and aggregation at physiological temperature (Furukawa and O’Halloran, 2005). In vitro aggregates of human SOD1 polypeptide without any modifications possess amyloid-like characters with fibrillar morphologies and show a seeding activity to accelerate fibrillation of native human SOD1 proteins (Furukawa et al., 2008). More importantly, amyloid-like fibrils of human apo-SOD1SH retain their seeding activity in the intracellular environment; transduction of those human SOD1 fibrils into cultured cells (mouse neuroblastoma, Neuro2a) has been shown to trigger the aggregation of stably-transfected human SOD1 (Furukawa et al., 2013).
fALS-causing mutations have been shown to decrease affinity for copper/zinc ions and/or stability of a disulfide bond (Hayward et al., 2002; Tiwari and Hayward, 2003; Furukawa et al., 2008). Therefore, in a reducing environment of the cytoplasm with high metal-chelating capacity, pathogenic mutations are supposed to increase intracellular fractions of fibrillation-prone apo-SOD1SH (Furukawa et al., 2008). Nonetheless, it remains unclear how mutant SOD1 forms aggregates under pathological conditions. To elucidate how SOD1 aggregates form, several pathways for aggregation have been proposed in SOD1 proteins in vitro (Furukawa, 2012b). As reported by Munch et al. mutant SOD1 was found to form fibrillo-granular aggregates by addition of trifluoroethanol (TFE; Münch and Bertolotti, 2010), which penetrated inside neuronal cells through macropinocytosis and then acted as seeds to trigger intracellular aggregation of endogenously expressed SOD1 variants (Münch et al., 2011). Once SOD1 aggregation occurs in a cell, the aggregates can be released to the extracellular space and then transferred from cell to cell (vide infra). Intracellular aggregation of mutant SOD1 is thus considered to be persistent and heritable after passages, supporting prion-like propagation of aggregation phenotypes.
As mentioned above, two distinct types of SOD1 aggregates, i.e., apo-SOD1SH amyloids and TFE-induced aggregates, have been found to function as seeds to trigger SOD1 aggregation intracellularly, but their structural and biochemical properties depend on how aggregation was induced (Furukawa et al., 2008; Münch and Bertolotti, 2010). Based upon previous in vitro studies, several distinct pathways for aggregation are possible in SOD1 (Toichi et al., 2013) and are expected to produce SOD1 aggregates with a varying degree of a seeding activity. This might describe heterologous progression and severity of diseases among SOD1-related fALS patients. Indeed, disease phenotypes of fALS cases have been known to be variable among different mutations in SOD1 (Wang et al., 2008), and furthermore, mutation-dependent structures of SOD1 fibrils closely correlate with their distinct biochemical properties (Furukawa et al., 2010). Therefore, it will be interesting to test if SOD1 fibrils with different mutations exhibit distinct activity as seeds in vitro and in vivo.
Propagation of Protein Misfolding in Amyotrophic Lateral Sclerosis (ALS)
In a seeding reaction, sheared pieces of insoluble fibrils can act as structural templates for a “phase-like transition” from soluble native conformers to generally insoluble fibrillar state, but this view now appears to be necessary for revision. Grad et al. utilized antibodies (3H1 and 10C12) that exclusively recognize misfolded SOD1 with disease-specific epitopes, which are not available in the natively folded state, and showed that misfolding of endogenous wild-type SOD1 in human cells (e.g., human embryonic kidney 293 cells (HEK293)) is induced by co-expression of a soluble misfolded form of human SOD1 with pathogenic mutations (Grad et al., 2011). In other words, soluble misfolded conformers of SOD1 are also transmissible without adopting classical, insoluble fibrillar states. Furthermore, transient expression of mutant human SOD1 in murine cells (e.g., Neuro2a) did not induce misfolding of endogenous mouse wild-type SOD1 (Grad et al., 2011). The difference lies in the amino acid sequence of murine and human SOD1, where the only tryptophan in human SOD1 (Trp32) is replaced by serine in murine counterpart. Indeed, misfolding of wild-type human SOD1 was observed by human SOD1 with a pathogenic (G127X) mutation but was significantly mitigated when G127X human SOD1 with W32S mutation was used (Grad et al., 2011). Trp32 in human SOD1 is highly solvent-exposed and distant from the native dimer interface, which might provide an alternative site for abnormal intermolecular interactions through hydrophobic interactions. It is interesting to note that expression of mutant TAR DNA binding protein 43 (TDP-43) and Fused in Sarcoma (FUS), pathogenic proteins also known to be found in ALS patients (Arai et al., 2006; Neumann et al., 2006; Kwiatkowski et al., 2009; Vance et al., 2009), can increase the immunoreactivity for misfolded SOD1 using a disease-specific antibody (3H1), both in patients and cultured human cells (SH-SY5Y; Pokrishevsky et al., 2012). While pathological involvement of wild-type SOD1 in ALS remains to be established, aberrant conformers of wild-type SOD1 have been reported in sporadic ALS with no genetic background (Furukawa, 2012a). Accordingly, toxic conformers of SOD1 might be produced by abnormal interactions of folded SOD1 with misfolded SOD1 or other proteins (such as TDP-43/FUS) at the site surrounding Trp32. In other words, as proposed in the template-assisted misfolding of prion proteins (Horwich and Weissman, 1997), soluble but misfolded conformers of protein molecules can be propagated through abnormal interactions among homologous proteins even without the formation of classical amyloid-like fibrils.
A Cell-to-Cell Transfer of Intracellular Superoxide Dismutase (SOD1)
SOD1 is known as one of major intracellular proteins, and most of SOD1 (~70%) exist in the cytoplasm (Chang et al., 1988). To confirm that seeded aggregation or misfolding of SOD1 is the key molecular mechanism of pathological propagation of SOD1-fALS, it is required to understand how intracellular misfolded/aggregated SOD1 is transferred from the cytoplasm to extracellular environment. As a relatively simple process, misfolded/aggregated SOD1 would be released to extracellular environment by death of an affected cell and then phagocytosed by the other cell. Recent studies have nonetheless suggested more sophisticated processes for a cell-to-cell transfer of SOD1 proteins (Grad et al., 2011; Münch et al., 2011). In fact, active secretion of SOD1 to extracellular space has been suggested in several different types of cultured cells (Mondola et al., 1996, 1998), and both wild-type and mutant SOD1 can be also detected in the cerebrospinal fluid of healthy controls as well as fALS patients (Zetterström et al., 2011).
In conditioned media of mouse motor neuron-like hybrid (NSC-34) cell line, impaired secretion of mutant SOD1 was associated with intracellular formation of inclusions and toxicity, suggesting secretion of mutant SOD1 as a beneficial process for cell survival (Turner et al., 2005). In contrast, Urushitani et al. have found that mutant SOD1 proteins are secreted in association with chromogranins and cause microgliosis and neuron death (Urushitani et al., 2006), leading to the idea that suppression of extracellular mutant SOD1 is a promising strategy for therapeutics of SOD1-related fALS cases. Indeed, passive as well as active immunizations targeting extracellular mutant SOD1 proteins have successfully prolonged lifespan of transgenic mice expressing mutant human SOD1 (Urushitani et al., 2007). Toxic roles of secreted SOD1 are further supported by the findings that motor neurons are killed by being co-cultured with astrocytes derived from adult neural progenitor cells isolated from post-mortem lumber spinal cord tissues from sporadic ALS as well as SOD1-related fALS (Haidet-Phillips et al., 2011). Also importantly, suppression of SOD1 in both fALS and sporadic ALS astrocytes was found to negate such toxicity of astrocytes toward motor neurons. Recently, furthermore, Basso et al. have shown the increased release of exosomes from astrocytes overexpressing fALS-causing mutant SOD1 and found that astrocyte-derived exosomes contained mutant SOD1 proteins and were transferred to the cytoplasm of spinal neurons (Basso et al., 2013).
Based upon these results, secretion of SOD1 is considered to occur through several distinct pathways and appears to be a normal physiological process. Experimental evidences are further required to show that secretory vesicles act as a messenger to generate seeding activity of SOD1. More specifically, conformational analysis of SOD1 (folded, misfolded, or fibrillized) included in those vesicles will reveal the molecular mechanism of pathological propagation in ALS through a seeding reaction.
Summary
As briefly summarized above, increasing numbers of recent studies have supported the idea that misfolding/aggregation of mutant SOD1 is transmissible through a seeding mechanism inside the cell and among cells. In that sense, it is interesting to test pathological roles, if any, of SOD3, which resides at the extracellular matrix and possesses a structural domain almost homologous to SOD1 (Folz and Crapo, 1994). A SOD1-like domain of SOD3 has been shown to exhibit propensities for aggregation (Son et al., 2003), implying its involvement in the formation of seeds that can be taken up by cells. In summary, a seeded aggregation of SOD1 proteins including wild-type SOD1 will be a key event to understand progression/propagation of pathological changes in SOD1-related fALS and even sALS cases without mutations in SOD1, and extracellular SOD1 with aberrant conformations is a promising target for therapeutics of those devastating diseases.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by Grants-in-Aid 24111542 for Scientific Research on Innovative Areas, 25291028 for Scientific Research (B), and 24657093 for Challenging Exploratory Research (to Yoshiaki Furukawa) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
References
Aguzzi, A., and Rajendran, L. (2009). The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64, 783–790. doi: 10.1016/j.neuron.2009.12.016
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., et al. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611. doi: 10.1016/j.bbrc.2006.10.093
Basso, M., Pozzi, S., Tortarolo, M., Fiordaliso, F., Bisighini, C., Pasetto, L., et al. (2013). Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J. Biol. Chem. 288, 15699–15711. doi: 10.1074/jbc.m112.425066
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., et al. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851–1854. doi: 10.1126/science.281.5384.1851
Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723–749. doi: 10.1146/annurev.neuro.27.070203.144244
Chang, L. Y., Slot, J. W., Geuze, H. J., and Crapo, J. D. (1988). Molecular immunocytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J. Cell. Biol. 107, 2169–2179. doi: 10.1083/jcb.107.6.2169
Chia, R., Tattum, M. H., Jones, S., Collinge, J., Fisher, E. M., and Jackson, G. S. (2010). Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis. PLoS One 5:e10627. doi: 10.1371/journal.pone.0010627
Dobson, C. M. (1999). Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329–332. doi: 10.1016/S0968-0004(99)01445-0
Folz, R. J., and Crapo, J. D. (1994). Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. Genomics 22, 162–171. doi: 10.1006/geno.1994.1357
Forman, H. J., and Fridovich, I. (1973). On the stability of bovine superoxide dismutase. The effects of metals. J. Biol. Chem. 248, 2645–2649.
Furukawa, Y. (2012a). Pathological roles of wild-type Cu,Zn-superoxide dismutase in amyotrophic lateral sclerosis. Neurol. Res. Int. 2012:323261. doi: 10.1155/2012/323261
Furukawa, Y. (2012b). “Protein aggregates in pathological inclusions of amyotrophic lateral sclerosis,” in Amyotrophic Lateral Sclerosis, ed M. H. Maurer (Rijeka, Croatia: InTech), 335–356.
Furukawa, Y., Kaneko, K., Watanabe, S., Yamanaka, K., and Nukina, N. (2013). Intracellular seeded aggregation of mutant Cu,Zn-superoxide dismutase associated with amyotrophic lateral sclerosis. FEBS Lett. 587, 2500–2505. doi: 10.1016/j.febslet.2013.06.046
Furukawa, Y., Kaneko, K., Yamanaka, K., and Nukina, N. (2010). Mutation-dependent polymorphism of Cu,Zn-superoxide dismutase aggregates in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 285, 22221–22231. doi: 10.1074/jbc.m110.113597
Furukawa, Y., Kaneko, K., Yamanaka, K., O’Halloran, T. V., and Nukina, N. (2008). Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in familial form of ALS. J. Biol. Chem. 283, 24167–24176. doi: 10.1074/jbc.m802083200
Furukawa, Y., and O’Halloran, T. V. (2005). Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo, reduced form of SOD1, leading to unfolding and oxidative aggregation. J. Biol. Chem. 280, 17266–17274. doi: 10.1074/jbc.m500482200
Furukawa, Y., Torres, A. S., and O’Halloran, T. V. (2004). Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS. EMBO J. 23, 2872–2881. doi: 10.1038/sj.emboj.7600276
Gibbs, C. J. Jr., Amyx, H. L., Bacote, A., Masters, C. L., and Gajdusek, D. C. (1980). Oral transmission of kuru, Creutzfeldt-Jakob disease and scrapie to nonhuman primates. J. Infect. Dis. 142, 205–208. doi: 10.1093/infdis/142.2.205
Grad, L. I., Guest, W. C., Yanai, A., Pokrishevsky, E., O’Neill, M. A., Gibbs, E., et al. (2011). Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc. Natl. Acad. Sci. U S A 108, 16398–16403. doi: 10.1073/pnas.1102645108
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824–828. doi: 10.1038/nbt.1957
Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356. doi: 10.1126/science.1072994
Harper, J. D., and Lansbury, P. T. Jr. (1997). Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407. doi: 10.1146/annurev.biochem.66.1.385
Hayward, L. J., Rodriguez, J. A., Kim, J. W., Tiwari, A., Goto, J. J., Cabelli, D. E., et al. (2002). Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 277, 15923–15931. doi: 10.1074/jbc.m112087200
Holmes, B. B., and Diamond, M. I. (2012). Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission? Ann. Neurol. 72, 832–836. doi: 10.1002/ana.23684
Horwich, A. L., and Weissman, J. S. (1997). Deadly conformations–protein misfolding in prion disease. Cell 89, 499–510. doi: 10.1016/s0092-8674(00)80232-9
Kanouchi, T., Ohkubo, T., and Yokota, T. (2012). Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J. Neurol. Neurosurg. Psychiatry 83, 739–745. doi: 10.1136/jnnp-2011-301826
Kato, S., Takikawa, M., Nakashima, K., Hirano, A., Cleveland, D. W., Kusaka, H., et al. (2000). New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 163–184. doi: 10.1080/14660820050515160
Kerman, A., Liu, H. N., Croul, S., Bilbao, J., Rogaeva, E., Zinman, L., et al. (2010). Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335–344. doi: 10.1007/s00401-010-0646-5
Kwiatkowski, T. J. Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208. doi: 10.1126/science.1166066
McCord, J. M., and Fridovich, I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049–6055.
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., et al. (2006). Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781–1784. doi: 10.1126/science.1131864
Mondola, P., Annella, T., Santillo, M., and Santangelo, F. (1996). Evidence for secretion of cytosolic CuZn superoxide dismutase by Hep G2 cells and human fibroblasts. Int. J. Biochem. Cell Biol. 28, 677–681. doi: 10.1016/1357-2725(96)00004-0
Mondola, P., Annella, T., Seru, R., Santangelo, F., Iossa, S., Gioielli, A., et al. (1998). Secretion and increase of intracellular CuZn superoxide dismutase content in human neuroblastoma SK-N-BE cells subjected to oxidative stress. Brain Res. Bull. 45, 517–520. doi: 10.1016/s0361-9230(97)00438-3
Morimoto, R. I. (2008). Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22, 1427–1438. doi: 10.1101/gad.1657108
Münch, C., and Bertolotti, A. (2010). Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J. Mol. Biol. 399, 512–525. doi: 10.1016/j.jmb.2010.04.019
Münch, C., O’Brien, J., and Bertolotti, A. (2011). Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U S A 108, 3548–3553. doi: 10.1073/pnas.1017275108
Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A. O., Riekel, C., Grothe, R., et al. (2005). Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773–778. doi: 10.1038/nature03680
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133. doi: 10.1126/science.1134108
Pokrishevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R., and Cashman, N. R. (2012). Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 7:e35050. doi: 10.1371/journal.pone.0035050
Polymenidou, M., and Cleveland, D. W. (2011). The seeds of neurodegeneration: prion-like spreading in ALS. Cell 147, 498–508. doi: 10.1016/j.cell.2011.10.011
Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144. doi: 10.1126/science.6801762
Ravits, J. M., and La Spada, A. R. (2009). ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805–811. doi: 10.1212/wnl.0b013e3181b6bbbd
Ridley, R. M., Baker, H. F., Windle, C. P., and Cummings, R. M. (2006). Very long term studies of the seeding of beta-amyloidosis in primates. J. Neural Transm. 113, 1243–1251. doi: 10.1007/s00702-005-0385-2
Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248–264. doi: 10.1038/nrn3430
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62. doi: 10.1038/364362c0
Ross, C. A., and Poirier, M. A. (2004). Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl.), S10–S17. doi: 10.1038/nm1066
Son, M., Cloyd, C. D., Rothstein, J. D., Rajendran, B., and Elliott, J. L. (2003). Aggregate formation in Cu,Zn superoxide dismutase-related proteins. J. Biol. Chem. 278, 14331–14336. doi: 10.1074/jbc.m211698200
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49–60. doi: 10.1038/nrn1007
Soto, C. (2012). Transmissible proteins: expanding the prion heresy. Cell 149, 968–977. doi: 10.1016/j.cell.2012.05.007
Tiwari, A., and Hayward, L. J. (2003). Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J. Biol. Chem. 278, 5984–5992. doi: 10.1074/jbc.m210419200
Toichi, K., Yamanaka, K., and Furukawa, Y. (2013). Disulfide scrambling describes the oligomer formation of superoxide dismutase (SOD1) proteins in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 288, 4970–4980. doi: 10.1074/jbc.m112.414235
Treusch, S., Cyr, D. M., and Lindquist, S. (2009). Amyloid deposits: protection against toxic protein species? Cell Cycle 8, 1668–1674. doi: 10.4161/cc.8.11.8503
Turner, B. J., Atkin, J. D., Farg, M. A., Zang, D. W., Rembach, A., Lopes, E. C., et al. (2005). Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. 25, 108–117. doi: 10.1523/jneurosci.4253-04.2005
Turner, B. J., and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94–134. doi: 10.1016/j.pneurobio.2008.01.001
Urushitani, M., Ezzi, S. A., and Julien, J. P. (2007). Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U S A 104, 2495–2500. doi: 10.1073/pnas.0606201104
Urushitani, M., Sik, A., Sakurai, T., Nukina, N., Takahashi, R., and Julien, J. P. (2006). Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9, 108–118. doi: 10.1038/nn1603
Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211. doi: 10.1126/science.1165942
Wang, J., Xu, G., Gonzales, V., Coonfield, M., Fromholt, D., Copeland, N. G., et al. (2002). Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 10, 128–138. doi: 10.1006/nbdi.2002.0498
Wang, Q., Johnson, J. L., Agar, N. Y., and Agar, J. N. (2008). Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 6:e170. doi: 10.1371/journal.pbio.0060170
Winklhofer, K. F., Tatzelt, J., and Haass, C. (2008). The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336–349. doi: 10.1038/sj.emboj.7601930
Keywords: SOD1, aggregation, seeding reaction, protein misfolding, amyloid
Citation: Ogawa M and Furukawa Y (2014) A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 8:83. doi: 10.3389/fncel.2014.00083
Received: 19 August 2013; Accepted: 03 March 2014;
Published online: 18 March 2014.
Edited by:
Ricardo Tapia, Universidad Nacional Autónoma de México, MexicoReviewed by:
Luis B. Tovar-y-Romo, Universidad Nacional Autónoma de México, MexicoNeil Cashman, University of British Columbia, Canada
Copyright © 2014 Ogawa and Furukawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yoshiaki Furukawa, Laboratory for Mechanistic Chemistry of Biomolecules, Department of Chemistry, Keio University, 3-14-1 Hiyoshi, Kohoku, Yokohama, Kanagawa 223-8522, Japan e-mail: furukawa@chem.keio.ac.jp